Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating Costs and Expenses:
General and administrative	$ 2,444,000	$ 1,303,000	$ 5,599,000	$ 3,988,000
Research and development	2,570,000	1,972,000	8,652,000	5,021,000
Total Operating Costs and Expenses	5,014,000	3,275,000	14,251,000	9,009,000
Loss from Operations	(5,014,000)	(3,275,000)	(14,251,000)	(9,009,000)
Other Expense:
Exchange loss	(9,000)		(40,000)
Interest income	170,000	2,000	197,000	4,000
Total Other Income(Expense)	161,000	2,000	157,000	4,000
Net Loss	(4,853,000)	(3,273,000)	(14,094,000)	(9,005,000)
Net Loss Attributable to Non-controlling Interest				(1,000)
Net Loss Attributable to Theriva Biologics, Inc. and Subsidiaries	(4,853,000)	(3,273,000)	(14,094,000)	(9,004,000)
Effect of Warrant exercise price adjustment	(340,000)		(340,000)
Effect of Series A Preferred Stock price adjustment			0	(7,402,000)
Net Loss Attributable to Common Stockholders	$ (5,193,000)	$ (3,273,000)	$ (14,434,000)	$ (17,926,000)
Net Loss Per Share - Basic	$ (0.33)	$ (0.25)	$ (0.95)	$ (1.51)
Net Loss Per Share - Dilutive	$ (0.33)	$ (0.25)	$ (0.95)	$ (1.51)
Weighted average number of shares outstanding during the period - Basic	15,844,061	13,204,254	15,176,927	11,844,863
Weighted average number of shares outstanding during the period - Dilutive	15,844,061	13,204,254	15,176,927	11,844,863
Series A Preferred Stock
Other Expense:
Preferred Stock Dividends				$ (24,000)
Effect of Series A Preferred Stock price adjustment				(7,402,000)
Series B Preferred Stock
Other Expense:
Net Loss Attributable to Non-controlling Interest				(100,000)
Preferred Stock Dividends				$ (1,497,000)